Blog

Antonio Passaro: Major Breakthrough Announced – MARIPOSA Study Results

Antonio Passaro/LinkedIn

Jan 8, 2025, 12:38

Antonio Passaro: Major Breakthrough Announced – MARIPOSA Study Results

Antonio Passaro, Medical Oncologist and a Medical Director with High Specialization Assignment at the European Institute of Oncology in Milan, shared a post on LinkedIn:

“Major Breakthrough Announced: MARIPOSA Study Results

The MARIPOSA study has demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) for patients with EGFR mutant NSCLC.

In anticipation of the full data, which will be presented soon, this press release marks an important milestone in lung cancer research, confirming a significant impact on the treatment landscape for EGFR-mutated cases.

2025 is shaping up to be a year filled with groundbreaking information and results in this setting.”

Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared this post, adding:

“Exciting news for those with EGFR+ NSCLC!”

More posts featuring Antonio Passaro and Amy Moore.

Antonio Passaro MD PhD, is a Medical Oncologist and a Medical Director with High Specialization Assignment at the European Institute of Oncology in Milan, specialising in lung cancer research and treatment. He focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC).

Dr. Antonio Passaro is an Associate Editor for Lung Cancer Journal by Elsevier and the Chair of the ESMO Press and Media Affairs Committee. He is also a faculty member for the Lung and Other Thoracic Tumours faculty group and the ESMO-MCBS Extended Working Group. He also holds editorial positions and key roles in societies like ESMO and AIOM.

Amy C. Moore is the Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation. She previously served as the Director of Science and Research at the Addario Lung Cancer Medical Institute (ALCMI).

She has published peer-reviewed papers on virology, cancer, and biomarker testing in NSCLC. Dr. Moore is also an expert on COVID-19’s impact on lung cancer and serves on several advisory boards.